
Commentary|Videos|January 13, 2023
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Creatine and Cancer Safety: Gabrielle Raucci Discusses Timing and Benefits
2
Ivermectin and Cancer: Navigating Patient Curiosity in Oncology Nursing
3
FDA Approves Perioperative Pembrolizumab-EV Regimen for MIBC
4
Navigating a Cancer Diagnosis While Pregnant as a Nurse
5


























































